briEf communicATions
Genetic engineering of human pluripotent cells using TALE nucleases
Dirk Hockemeyer1,4, Haoyi Wang1,4, Samira Kiani1,
Christine S Lai1,2, Qing Gao1, John P Cassady1,2, Gregory J Cost3, Lei Zhang3, Yolanda Santiago3, Jeffrey C Miller3, Bryan Zeitler3, Jennifer M Cherone3, Xiangdong Meng3, Sarah J Hinkley3, Edward J Rebar3, Philip D Gregory3, Fyodor D Urnov3 & Rudolf Jaenisch1,2
Targeted genetic engineering of human pluripotent cells is a prerequisite for exploiting their full potential. Such genetic manipulations can be achieved using site-specific nucleases. Here we engineered transcription activator–like effector nucleases (TALENs) for five distinct genomic loci. At all loci tested we obtained human embryonic stem cell (ESC) and
induced pluripotent stem cell (iPSC) clones carrying transgenic cassettes solely at the TALEN-specified location. Our data suggest that TALENs employing the specific architectures described here mediate site-specific genome modification in human pluripotent cells with similar efficiency and precision as do zinc-finger nucleases (ZFNs).
Gene targeting of human pluripotent cells by homologous recombination is inefficient, which has impeded the use of human ESCs and iPSCs in disease models. To overcome this limitation, we and others have shown that ZFNs can be used to modify the genomes of ESCs and iPSCs1–3. ZFNs can be engineered to induce a double-strand break precisely at a predetermined position in the genome4. The double-strand break can be repaired through nonhomologous end-joining to drive targeted gene disruption or through the homology-directed DNA repair pathway using an exogenous donor plasmid as a template. Depending on the donor design, this repair reaction can be used to generate large-scale deletions, gene disruptions, DNA addition4 or single-nucleotide changes5.
Recent work on transcription activator–like effectors (TALEs) provides an alternative approach to the design of site-specific nucleases6. Natural TALEs are transcription factors used by plant pathogens to subvert host genome regulatory networks6. The DNA-binding domain of TALEs is unusual. Multiple units of ~34 amino acids (called TALE repeats) are arranged in tandem, their sequence nearly identical except for two highly variable amino acids that establish the base-recognition specificity of each unit7,8. Each individual domain determines the specificity of binding to one DNA base pair in the TALE recognition sequence, and there-fore arrays of four different repeat units are sufficient to generate TALEs with novel DNA recognition sites7,8. Nucleases based on such engineered TALE domains have been shown to target endogenous genes in trans-
formed human cells9,10. Here we evaluate the use of TALENs for genetic engineering of endogenous loci in human ESCs and iPSCs.
We designed TALENs targeting the PPP1R12C (the AAVS1 locus), OCT4 (also known as POU5F1) and PITX3 genes at precisely the same positions as targeted earlier by ZFNs2. TALEN expression constructs and corresponding donor plasmids bearing homologous sequences were introduced into ESCs (line WIBR#3)11 and iPSCs (line C1)12 by elec-troporation (Supplementary Fig. 1 and Supplementary Tables 1 and 2). Southern blot analysis was used to identify correctly targeted clones.We targeted PPP1R12C with a gene trap approach (expressing puro-mycin (Puro) from the endogenous gene; Fig. 1a,b and Table 1) or with an autonomous selection cassette (puromycin expressed from the PGK-promoter (Fig. 1, Table 1 and Supplementary Figs. 1–3). Targeting efficiency was high and similar to that with ZFNs2: 50% of the clones were targeted in one or both alleles and carried no randomly integrated transgenes (Fig. 1b, Table 1 and Supplementary Fig. 2). Similarly, an SA-Puro-CAGGS-eGFP transgene was highly expressed from this locus (Fig. 1a and Supplementary Fig. 3a,b). Notably, such targeted cells remained pluripotent based on analysis of marker expression and of tera-tomas. (Supplementary Fig. 3c–e). Cells of all germ layers in teratomas expressed eGFP, indicating that TALEN- as well as ZFN-mediated target-ing of PPP1R12C results in robust transgene expression in pluripotent as well as in differentiated cells (Supplementary Fig. 3a,b,d,e).
OCT4 was targeted using three different donor plasmids, resulting in expression of puromycin and an OCT4 exon1-eGFP fusion protein under control of the endogenous OCT4 promoter. The first two donor plasmids were designed to integrate a splice acceptor-eGFP-2A-Puro cassette into the first intron of OCT4, whereas the third donor generated an in-frame fusion of exon 1 with the eGFP-2A-Puro cassette (Supplementary Fig. 4). Targeting efficiency in ESCs and iPSCs was 70–100% as determined by Southern blot analysis and DNA sequencing of single cell–derived clones (Table 1 and Supplementary Figs. 1 and 4).
We also targeted the first exon of PITX3, which is not expressed in human pluripotent cells, and found that ~6% of drug-resistant clones carried the transgene solely at the PITX3 locus as evaluated by Southern blot analysis (Table 1 and Supplementary Figs. 1 and 5). Notably, in one clone the transgene had integrated into both alleles of PITX3.
To target the C terminus of OCT4, which has not been previously targeted by ZFNs, we generated TALENs directed against sequences flanking the stop codon of OCT4 using two donor plasmids: the last OCT4 codon was either fused in frame with an eGFP-PGK-Puro con-struct or with eGFP preceded by a 2A sequence (2A-eGFP-PGK-Puro; Fig. 1c and Table 1). After excision of the LoxP-flanked PGK-Puro cas-settes, either a C-terminal OCT4-eGFP fusion protein or a separately translated eGFP protein will be expressed under the control of endog-enous OCT4 (ref. 13). Southern blot analysis showed that 2–10% of single cell–derived ESC and iPSC clones carried the transgene cassette at the OCT4 locus (Fig. 1d,e and Table 1). Cre-mediated excision of the PGK-
© 2011 Nature America, Inc. All rights reserved

.
Massachusetts, USA.3Sangamo BioSciences, Inc., Richmond, California, USA. 4These authors contributed equally to this work. Correspondence should be addressed to R.J. (jaenisch@wi.mit.edu).
Received 11 March; accepted 28 June; published online 7 July 2011; doi:10.1038/nbt.1927
1The Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. 2Department of Biology, Massachusetts Institute of Technology, Cambridge,
nature biotechnology volume 29 number 8 august 2011 731
transcription activator-like (TAL) effector nucleases Ⅰ 工具酶的功能分类: ...干细胞 《Genetic engineering of human pluripotent cells using TALE nucleases》...
? 一篇人类干细胞 《Genetic engineering of human pluripotent cells using TALE nucleases》 ? 一篇大鼠 《Knockout rats generated by embryo microinjection of ...
? 一篇人类干细胞 《Genetic engineering of human pluripotent cells using TALE nucleases》 ? 一篇大鼠 《Knockout rats generated by embryo microinjection of ...
? 一篇人类干细胞 《Genetic engineering of human pluripotent cells using TALE nucleases》 ? 一篇大鼠 《Knockout rats generated by embryo microinjection of ...
Genetic engineering of human ES and iPS cells using TALE nucleases Dirk ...expression in pluripotent as well as in differentiated cells (Figure S3C–E...
? 一篇人类干细胞 《Genetic engineering of human pluripotent cells using TALE nucleases》 ? 一篇大鼠 《Knockout rats generated by embryo microinjection of ...
? 一篇人类干细胞 《Genetic engineering of human pluripotent cells using TALE nucleases》 ? 一篇大鼠 《Knockout rats generated by embryo microinjection of ...
Genetic engineering of human pluripotent cells using TALE nucleases[J]. Nature biotechnology, 2011, 29(8): 731-734. 2. 人(miR-155*) : 3. 小鼠:...
? 一篇人类干细胞 《Genetic engineering of human pluripotent cells using TALE nucleases》 ? 一篇大鼠 《Knockout rats generated by embryo microinjection of ...
? 一篇人类干细胞 《Genetic engineering of human pluripotent cells using TALE nucleases》 ? 一篇大鼠 《Knockout rats generated by embryo microinjection of ...
热门文档